Small-molecule STAT3 Signaling Pathway Modulators from Polygonum cuspidatum

 

 Buy Article Permissions and Reprints

Abstract

Constitutively activated STAT3 plays a pivotal role in oncogenesis and metastasis in many human cancers, and STAT3 has been validated as a novel anticancer drug target. Thus, the identification of small molecules that modulate STAT3 activity could be of great therapeutic importance. The aim of this study was to isolate novel modulators of the STAT3 signaling pathway from the roots of Polygonum cuspidatum by bioassay-guided fractionation using a STAT3 reporter gene assay. 2-Methoxystypandrone (1), as well as three anthraquinones (2–4), were identified as major active components of P. cuspidatum. Compound 1 demonstrated a potent inhibitory effect on STAT3 activation and significantly inhibited cell proliferation of human breast cancer cells, especially those with constitutively activated STAT3 (IC₅₀ = 2.7–3.1 µM). The SAR analysis of quinone analogues suggested that the phenolic and carbonyl groups are the key structures contributing to their inhibitory activities against the STAT3 signaling.

^* These authors contributed equally to this work.

• References

• 1 Bromberg JF, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-2473
  CrossrefPubMedGoogle Scholar
• 2 Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE. STAT3 as an oncogene. Cell 1999; 98: 295-303
  CrossrefPubMedGoogle Scholar
• 3 Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009; 9: 626-633
  CrossrefPubMedGoogle Scholar
• 4 Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167: 969-980
  CrossrefPubMedGoogle Scholar
• 5 Turkson J. STAT proteins as novel targets for cancer drug discovery. Exp Opin Ther Targets 2004; 8: 409-422
  CrossrefPubMedGoogle Scholar
• 6 Pharmacopoeia of China, Part 1. Beijing: Peopleʼs Health Press; 2010: 194-195
  Google Scholar
• 7 Pan M, Wang X. Chemical constituents and pharmacological action of Polygonum cuspidatum Sieb. et Zucc. J Chin Med Mater 2000; 23: 56-58
  PubMedGoogle Scholar
• 8 Hughes AB, Sargent MV. Synthesis of 2-methoxystypandrone: comments on the structure of ventilaginone. J Chem Soc [Perkin I] 1989; 1: 449-452
  PubMedGoogle Scholar
• 9 Buchalter L. Isolation and identification of emodin (1,3,8-tri-hydroxy-6-methyl anthraquinone) from Rumex hymenosepalus, family Polygonaceae. J Pharm Sci 1969; 58: 904
  CrossrefPubMedGoogle Scholar
• 10 Demuth G, Hinz H, Seligmann O, Wagner H. Investigations on anthrachinonglycosides of Rhamnus species. V. Emodin-8-O-beta-gentiobioside,a new O-glycoside from Rhamnus frangula . Planta Med 1978; 33: 53-56
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 King NM. Isolation of physcion from Ditremexa occidentalis . J Am Pharm Assoc 1957; 46: 271-272
  PubMedGoogle Scholar
• 12 Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, Uchida T, Asakura K, Nakazato T, Kaneda T, Kizaki M, Ikeda Y, Yoshida T. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007; 6: 987-994
  PubMedGoogle Scholar
• 13 Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of STAT3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006; 12: 20-28
  CrossrefPubMedGoogle Scholar
• 14 Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20: 2499-2513
  CrossrefPubMedGoogle Scholar
• 15 Chiou WF, Liao JF, Huang CY, Chen CC. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes. Br J Pharmacol 2010; 161: 321-335
  CrossrefPubMedGoogle Scholar

• Supplementary Material